Education
About Us
Working with TipRanks
Follow Us
Idorsia Ltd (CH:IDIA)
:IDIA
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
―Last Year’s EPS
0.11Same Quarter Last Year
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 04, 2025
|% Change Since: -16.13%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Neutral
The earnings call conveyed a balanced sentiment. While Idorsia faced challenges, such as the failed licensing agreement for aprocitentan and financial pressures leading to cost reductions, it also highlighted significant achievements. These included QUVIVIQ's market expansion and sales growth in Europe, Canada, and the US, and strategic financial maneuvers that ensured stability and future funding. Overall, the company is maneuvering through its challenges with a focus on growth and financial stability.Company Guidance
During the call, Idorsia provided guidance for 2025, with the expectation of reaching CHF 110 million in sales for QUVIVIQ, driven by strong performance in the EUCAN region. The company anticipates a non-GAAP EBIT loss of CHF 215 million, a significant improvement from previous years, thanks to cost reductions and a restructuring of their convertible bonds. This includes a CHF 100 million reduction in R&D commitments and a new CHF 150 million funding facility. The US GAAP result is projected at CHF 155 million, incorporating these financial maneuvers. Idorsia remains focused on securing partnerships for their pipeline assets, particularly aprocitentan, to further stabilize and extend their financial runway.QUVIVIQ European and Canadian Market Expansion
QUVIVIQ is now available in nine countries across Europe and Canada, achieving CHF 32 million in net sales in 2024. Sales have shown a steady increase, with significant acceleration in Q4 driven by Germany and France.
US Sales Growth Despite Reduced Investments
QUVIVIQ's US sales grew to over CHF 28 million in 2024 despite a reduction in marketing and selling investments, showing steady growth.
Financial Stability Achieved Through Strategic Measures
Idorsia reduced its R&D commitment by US$100 million and restructured its convertible bonds, securing a new money facility of CHF 150 million, ensuring funds well into 2026.
Aprocitentan Approval and Launch Plans
TRYVIO (aprocitentan) received approval in the US and EU, with preparations for a focused launch in the US ongoing despite previous licensing setbacks.
---
CH:IDIA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CH:IDIA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 04, 2025 | CHF1.24 | CHF1.18 | -4.84% |
| Oct 29, 2024 | CHF1.18 | CHF1.18 | 0.00% |
| Jul 25, 2024 | CHF2.32 | CHF2.74 | +18.10% |
| May 21, 2024 | CHF2.22 | CHF2.18 | -1.80% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Idorsia Ltd (CH:IDIA) report earnings?
Idorsia Ltd (CH:IDIA) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is Idorsia Ltd (CH:IDIA) earnings time?
Idorsia Ltd (CH:IDIA) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Idorsia Ltd stock?
The P/E ratio of Idorsia Ltd is N/A.
What is CH:IDIA EPS forecast?
Currently, no data Available
---